Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITRM NASDAQ:KPRX NASDAQ:MRSN NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITRMIterum Therapeutics$0.74-0.8%$0.88$0.66▼$3.02$33.22M2.851.08 million shs623,818 shsKPRXKiora Pharmaceuticals$2.73+4.2%$2.85$2.25▼$4.18$9.37M-0.6486,822 shs27,058 shsMRSNMersana Therapeutics$7.75-4.4%$7.84$5.21▼$70.75$38.68M0.83123,104 shs71,731 shsOKUROnKure Therapeutics$2.83+4.4%$2.40$1.70▼$20.00$38.29M0.4131,645 shs59,581 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITRMIterum Therapeutics0.00%-13.80%-9.82%-20.15%-42.77%KPRXKiora Pharmaceuticals0.00%-6.83%-10.49%-10.78%-33.41%MRSNMersana Therapeutics0.00%+8.24%-3.76%-12.01%-77.70%OKUROnKure Therapeutics0.00%+11.86%+19.41%+31.63%+282,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITRMIterum Therapeutics1.8423 of 5 stars3.53.00.00.00.61.70.0KPRXKiora Pharmaceuticals2.7578 of 5 stars3.35.00.00.01.11.70.6MRSNMersana Therapeutics4.2229 of 5 stars3.54.00.04.11.82.50.0OKUROnKure Therapeutics3.2036 of 5 stars3.60.00.00.02.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITRMIterum Therapeutics 3.00Buy$9.001,109.68% UpsideKPRXKiora Pharmaceuticals 2.50Moderate Buy$10.00266.30% UpsideMRSNMersana Therapeutics 3.00Buy$56.60630.32% UpsideOKUROnKure Therapeutics 3.14Buy$32.331,042.52% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, ITRM, OKUR, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.008/13/2025KPRXKiora PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025OKUROnKure TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AKPRXKiora Pharmaceuticals$16.02M0.58$1.24 per share2.20$8.58 per share0.32MRSNMersana Therapeutics$40.50M0.95N/AN/A($1.92) per share-4.04OKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%N/AKPRXKiora Pharmaceuticals$3.60M-$2.910.00N/AN/AN/A-47.17%-34.00%N/AMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%-990.16%-54.85%11/12/2025 (Estimated)OKUROnKure Therapeutics-$52.67M-$4.800.00N/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)Latest KPRX, ITRM, OKUR, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/12/2025Q2 2025OKUROnKure Therapeutics-$1.23-$1.14+$0.09-$1.14N/AN/A8/8/2025Q2 2025KPRXKiora Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$0.75 million$0.75 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITRMIterum TherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITRMIterum TherapeuticsN/A2.692.52KPRXKiora PharmaceuticalsN/A7.767.76MRSNMersana TherapeuticsN/A1.351.35OKUROnKure TherapeuticsN/A11.1311.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITRMIterum Therapeutics9.21%KPRXKiora Pharmaceuticals76.97%MRSNMersana Therapeutics93.92%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipITRMIterum Therapeutics2.40%KPRXKiora Pharmaceuticals0.05%MRSNMersana Therapeutics13.00%OKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITRMIterum Therapeutics1044.66 million43.59 millionNot OptionableKPRXKiora Pharmaceuticals103.43 million3.43 millionNot OptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableOKUROnKure TherapeuticsN/A13.53 million11.11 millionN/AKPRX, ITRM, OKUR, and MRSN HeadlinesRecent News About These CompaniesBrokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33August 22 at 2:15 AM | americanbankingnews.comCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comLeerink Partnrs Has Positive Forecast for OKUR Q3 EarningsAugust 16, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)August 15, 2025 | theglobeandmail.comOnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)August 12, 2025 | msn.comOnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comBuy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial PositionJune 3, 2025 | tipranks.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure increased R&D spending in 1Q with drug trials underwayMay 7, 2025 | bizwest.comBOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPRX, ITRM, OKUR, and MRSN Company DescriptionsIterum Therapeutics NASDAQ:ITRM$0.74 -0.01 (-0.80%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.76 +0.02 (+2.42%) As of 08/22/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Kiora Pharmaceuticals NASDAQ:KPRX$2.73 +0.11 (+4.20%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.68 -0.05 (-1.83%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Mersana Therapeutics NASDAQ:MRSN$7.75 -0.36 (-4.44%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.76 +0.01 (+0.19%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.OnKure Therapeutics NASDAQ:OKUR$2.83 +0.12 (+4.43%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.82 -0.01 (-0.35%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access